[Articles] Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (MASTERPLAN): an open-label, phase 2, multicentre, randomised trial of the Australasian Gastro-Intestinal Trials Group
Start here
The open-label, phase 2, multicentre MASTERPLAN randomised trial by the Australasian Gastro-Intestinal Trials Group (AGITG) showed that perioperative chemotherapy plus SBRT significantly reduced locoregional recurrence in high-risk, localised PDAC. Compared with perioperative chemotherapy alone, adding SBRT did not significantly increase toxicity; the authors say the strategy warrants investigation in larger studies.
Excerpted from thelancet.com
Coverage timeline
Follow the coverage to see the different angles.
- thelancet.com[Articles] Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (MASTERPLAN): an open-label, phase 2, multicentre, randomised trial of the Australasian Gastro-Intestinal Trials Group
The open-label, phase 2, multicentre MASTERPLAN randomised trial by the Australasian Gastro-Intestinal Trials Group (AGITG) showed that perioperative chemotherapy plus SBRT significantly reduced locoregional recurrence in high-risk, localised PDAC. Compared with perioperative chemotherapy alone, adding SBRT did not significantly increase toxicity; the authors say the strategy warrants investigation in larger studies.
Heat trend for this story
Heat now 1·Peak in the comparable set 10 (Oct 24 01:00)·Change over 24h in the comparable set -50%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.